ISRCTN13404264已完成未知
Supporting people with type 2 diabetes in effective use of their medicine through a system comprising mobile health technology integrated with clinical care compared with usual care: a randomised feasibility trial
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 209
研究概览
简要总结
2021 Other publications in https://pubmed.ncbi.nlm.nih.gov/33769299/ describes the SMS-based system developed for and evaluated in SuMMiT-D (added 29/03/2021) 2022 Results article in https://pubmed.ncbi.nlm.nih.gov/35486430/ influence on psychological constructs that predict adherence (added 03/05/2022) 2019 Protocol article in http://dx.doi.org/10.1136/bmjopen-2019-033504 (added 17/11/2023) 2024 Results article in https://pubmed.ncbi.nlm.nih.gov/38273420/ feasibility results (added 30/01/2024)
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •Current participant inclusion criteria as of 04/01/2019:
- •COHORT 1 (people with diabetes):
- •1. Participant is willing and able to give informed consent for participation in the trial
- •2. Male or female, =35 years of age
- •3. Type 2 diabetes
- •4. Taking oral glucose lowering treatment, blood pressure lowering treatment or lipid lowering treatment either alone or in combination
- •5. Has access to a mobile phone and is able, if necessary with help (e.g. relative, friend, neighbour), to send, understand and retrieve brief SMS text-messages in the English language
- •6. The participant's practice is taking part in the trial
- •COHORT 2 (health care professionals):
- •Any health care professionals (including doctors, nurses, receptionists, practices managers and pharmacists) involved in the care of patients recruited to the trial.
- •Previous participant inclusion criteria:
- •COHORT 1 (people with diabetes):
- •1. Participant is willing and able to give informed consent for participation in the trial
- •2. Male or female, =35 years of age
- •3. Type 2 diabetes
- •4. Taking oral glucose lowering treatment, blood pressure lowering treatment or lipid lowering treatment either alone or in combination
- •5. Has started one or more of these medications or had a change in one of these medications within the last three months
- •6. Has access to a mobile phone and is able, if necessary with help (e.g. relative, friend, neighbour), to send, understand and retrieve brief SMS text-messages in the English language
- •7. The participant's practice is taking part in the trial
- •COHORT 2 (health care professionals):
- •Any health care professionals (including doctors, nurses, receptionists, practices managers and pharmacists) involved in the care of patients recruited to the trial.
排除标准
- •COHORT 1 (people with diabetes):
- •1. Female participant who is pregnant, within three months post-partum or planning pregnancy during the course of the trial
- •2. A serious medical condition that, in the opinion of the investigator makes them ineligible
- •3. Insulin treatment without also concomitant use of oral glucose lowering treatment
- •4. Another person in the household already participates in the trial
- •5. Patient has been admitted to hospital within the last three months for hyper- or hypoglycaemia (self-report)
- •COHORT 2 (health care professionals):
- •No exclusions
研究者
相似试验
进行中（未招募）
不适用
Support through mobile messaging and digital health technology for diabetesType 2 diabetes mellitusNutritional, Metabolic, EndocrineISRCTN15952379niversity of Oxford1,039
已完成
不适用
Mobile health for type 2 diabetesType 2 diabetesNutritional, Metabolic, EndocrineType 2 diabetes mellitusISRCTN14335124iverpool John Moores University125
招募中
Unknown
Digitally integrated care for type 2 diabetes and periodontitisE11K05.2K05.3Type 2 diabetes mellitusAcute periodontitisChronic periodontitisDRKS00030587niversitätsklinikum Heidelberg - Sektion Translationale Gesundheitsökonomie4,640
Unknown
不适用
Using Mobile Phone Short Message Service (SMS) Reminders to Enhance Appointment Attendance in DM PatientsAppointments and SchedulesDiabetes Mellitus, Type 2NCT03055702The University of Hong Kong270
已完成
不适用
mHealth Intervention to Support Diabetes Medication AdherenceDiabetes Mellitus, Type 2NCT05006872Fundació d'investigació Sanitària de les Illes Balears742